Chemical modification of the multitarget neuroprotective compound fisetin.

Many factors are implicated in age-related central nervous system (CNS) disorders, making it unlikely that modulating only a single factor will provide effective treatment. Perhaps a better approach is to identify small molecules that have multiple biological activities relevant to the maintenance of brain function. Recently, we identified an orally active, neuroprotective, and cognition-enhancing molecule, the flavonoid fisetin, that is effective in several animal models of CNS disorders. Fisetin has direct antioxidant activity and can also increase the intracellular levels of glutathione (GSH), the major endogenous antioxidant. In addition, fisetin has both neurotrophic and anti-inflammatory activity. However, its relatively high EC(50) in cell based assays, low lipophilicity, high topological polar surface area (tPSA), and poor bioavailability suggest that there is room for medicinal chemical improvement. Here we describe a multitiered approach to screening that has allowed us to identify fisetin derivatives with significantly enhanced activity in an in vitro neuroprotection model while at the same time maintaining other key activities.

[1]  P. Maher,et al.  Fisetin Lowers Methylglyoxal Dependent Protein Glycation and Limits the Complications of Diabetes , 2011, PloS one.

[2]  Xin Wang,et al.  Central nervous system agents for ischemic stroke: neuroprotection mechanisms. , 2011, Central nervous system agents in medicinal chemistry.

[3]  P. Maher,et al.  Control of redox state and redox signaling by neural antioxidant systems. , 2011, Antioxidants & redox signaling.

[4]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[5]  J. Purcell,et al.  ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. , 2011, Human molecular genetics.

[6]  J. Kraus,et al.  Neuroprotective Effects of N‐Alkyl‐1,2,4‐oxadiazolidine‐3,5‐diones and Their Corresponding Synthetic Intermediates N‐Alkylhydroxylamines and N‐1‐Alkyl‐3‐carbonyl‐1‐hydroxyureas against in vitro Cerebral Ischemia , 2010, ChemMedChem.

[7]  P. Maher Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin , 2009, Genes & Nutrition.

[8]  P. Maher,et al.  Lactacidosis modulates glutathione metabolism and oxidative glutamate toxicity , 2009, Journal of neurochemistry.

[9]  L. Su,et al.  Sulfuric Acid Promoted Condensation Cyclization of 2‐(2‐(Trimethylsilyl)ethynyl)anilines with Arylaldehydes in Alcoholic Solvents: An Efficient One‐Pot Synthesis of 4‐Alkoxy‐2‐arylquinolines , 2009 .

[10]  J. Kraus,et al.  Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity. , 2009, Journal of medicinal chemistry.

[11]  L. Su,et al.  Sulfuric acid promoted condensation cyclization of 2-(2-(trimethylsilyl) ethynyl)anilines with arylaldehydes in alcoholic solvents: an efficient one-pot synthesis of 4-alkoxy-2-arylquinolines , 2009 .

[12]  Christian Gerloff,et al.  Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. , 2009, Stroke.

[13]  S. Kuo,et al.  Metabolism and pharmacokinetics of 3,3',4',7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. , 2009, Journal of agricultural and food chemistry.

[14]  K. Suk,et al.  Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. , 2008, International immunopharmacology.

[15]  Spencer J. Williams,et al.  Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity. , 2008, Journal of medicinal chemistry.

[16]  P. Maher,et al.  A novel approach to screening for new neuroprotective compounds for the treatment of stroke , 2007, Brain Research.

[17]  M. Pangalos,et al.  Drug development for CNS disorders: strategies for balancing risk and reducing attrition , 2007, Nature Reviews Drug Discovery.

[18]  E. Castellano,et al.  Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships. , 2007, Bioorganic & medicinal chemistry.

[19]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[20]  A. Shuaib,et al.  Therapeutic strategies for the treatment of stroke. , 2006, Drug discovery today.

[21]  P. Maher A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives , 2006, Free radical research.

[22]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[23]  P. Maher,et al.  Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal‐regulated kinase activation , 2004, Journal of neurochemistry.

[24]  Han-Wei Chu,et al.  Regioselective hydroxylation of 2-hydroxychalcones by dimethyldioxirane towards polymethoxylated flavonoids , 2004 .

[25]  Yael Bromberg,et al.  Reactive oxygen species play an important role in iodoacetate-induced neurotoxicity in primary rat neuronal cultures and in differentiated PC12 cells , 2003, Neuroscience Letters.

[26]  B. S. Winkler,et al.  Modulation of the Pasteur effect in retinal cells: implications for understanding compensatory metabolic mechanisms. , 2003, Experimental eye research.

[27]  P. Maher,et al.  Oxytosis: A novel form of programmed cell death. , 2001, Current topics in medicinal chemistry.

[28]  I. Gozes,et al.  VIP-related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells , 2000, Journal of Molecular Neuroscience.

[29]  C. Oliveira,et al.  Distinct Glycolysis Inhibitors Determine Retinal Cell Sensitivity to Glutamate-Mediated Injury , 1999, Neurochemical Research.

[30]  P. Lipton,et al.  Ischemic cell death in brain neurons. , 1999, Physiological reviews.

[31]  A. Reshef,et al.  Activation and inhibition of protein kinase C protect rat neuronal cultures against ischemia-reperfusion insult , 1997, Neuroscience Letters.

[32]  W. Mathews,et al.  The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  H. Ueda,et al.  3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors. , 1993, Journal of medicinal chemistry.

[34]  P. Reiner,et al.  A pharmacological model of ischemia in the hippocampal slice , 1990, Neuroscience Letters.

[35]  W. Schaffner,et al.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. , 1989, Nucleic acids research.

[36]  H. Kourai,et al.  Syntheses of 5,6,7- and 5,7,8-trioxygenated 3',4'-dihydroxyflavones having alkoxy groups and their inhibitory activities against arachidonate 5-lipoxygenase. , 1986, Journal of medicinal chemistry.

[37]  P. Andrews,et al.  A common structural model for central nervous system drugs and their receptors. , 1986, Journal of medicinal chemistry.